Frank Rimerman Advisors’s Novo Nordisk NVO Stock Holding History

Frank Rimerman Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Buy	23,258 +795	+4%	+$34.2K	0.06%	228
2026 Q1	$826K	Sell	22,463 -7,606	-25%	-$360K	0.05%	273
2025 Q4	$1.53M	Buy	30,069 +8,403	+39%	+$430K	0.1%	167
2025 Q3	$1.2M	Sell	21,666 -3,949	-15%	-$231K	0.08%	205
2025 Q2	$1.77M	Buy	25,615 +4,173	+19%	+$284K	0.12%	134
2025 Q1	$1.49M	Sell	21,442 -199	-0.9%	-$16.4K	0.12%	139
2024 Q4	$1.86M	Sell	21,641 -21,417	-50%	-$2.32M	0.14%	113
2024 Q3	$5.13M	Buy	43,058 +43	+0.1%	+$5.74K	0.36%	41
2024 Q2	$6.14M	Buy	43,015 +42,727	+14,836%	+$5.66M	0.43%	29
2024 Q1	$37K	Hold	288	–	–	0.01%	134
2023 Q4	$29.8K	Buy	+288	New	+$28.5K	0.01%	133

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Frank Rimerman Advisors's NVO Position: Q2 2026 in Review

Frank Rimerman Advisors increased its Novo Nordisk (NVO) stake by 3.5% in Q2 2026, buying an estimated $34.2K and bringing the position to 23,258 shares worth $1.11M. The position accounts for 0.06% of the portfolio, ranked #228.

Frank Rimerman Advisors first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.14M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Frank Rimerman Advisors held 23,258 shares of Novo Nordisk worth $1.11M as of Q2 2026.
Frank Rimerman Advisors bought 795 Novo Nordisk shares in Q2 2026, an estimated $34.2K.
Novo Nordisk made up 0.06% of Frank Rimerman Advisors's portfolio in Q2 2026, its #228 holding.
Frank Rimerman Advisors first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
Frank Rimerman Advisors's Novo Nordisk position peaked at $6.14M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.